Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
METADATE ER vs ADDERALL 5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.
Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy (off-label)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.
Terminal elimination half-life: 3-6 hours (mean 4.5 hours) for methylphenidate; clinical context: requires multiple daily dosing or extended-release formulation.
Immediate-release: 9–11 hours (mean 10 hours for dextroamphetamine); extended-release: 10–13 hours. Terminal half-life may be prolonged with urinary p H >7.
Primarily hepatic via carboxylesterase CES1A1 to inactive metabolite ritalinic acid. Minor pathways include oxidative metabolism via CYP2D6. The drug undergoes extensive first-pass metabolism.
Amphetamine is metabolized via CYP2D6, with deamination and oxidation as major pathways.
Renal (80% as metabolites, <1% unchanged); fecal (10-20%) via biliary elimination.
Renal (90% as unchanged drug and metabolites; ~30% unchanged), minor fecal elimination (<5%).
10-33% (primarily albumin).
~16% bound to plasma proteins (primarily albumin).
Vd: 2-4 L/kg; indicates extensive tissue distribution and penetration into the central nervous system.
3.5–4.5 L/kg; indicates extensive tissue distribution (e.g., brain, lungs).
Oral: 30% (due to first-pass metabolism); Metadate ER: similar to immediate-release with extended dissolution profile.
Oral immediate-release: 96–100% (first-pass metabolism minimal); extended-release: approximately 96% relative to immediate-release.
No specific guidelines; use with caution in severe renal impairment (e GFR <30 m L/min/1.73m²) and consider dose reduction based on tolerability.
GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: use maximum of 50% of usual dose; not recommended in ESRD.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Not recommended.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: avoid use.
Age ≥6 years: Initial 10-20 mg orally once daily; increase by 10 mg weekly. Maximum: 60 mg/day or 2 mg/kg/day, whichever is less.
Children 3-5 years: initial 2.5 mg daily, increase by 2.5 mg weekly; max 40 mg/day. Children ≥6 years: initial 5 mg once or twice daily, increase by 5 mg weekly; max 40 mg/day (or 20 mg/day for extended-release).
Initiate at lower doses (e.g., 10 mg once daily) with cautious titration due to increased sensitivity and higher risk of adverse effects such as hypertension, agitation, and insomnia.
Initiate at 2.5 mg once or twice daily; increase by 2.5-5 mg weekly; monitor for cardiovascular effects and confusion.
METADATE ER has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events. Physicians should assess the risk of abuse before prescribing and monitor for signs of abuse during therapy.
Adderall has a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Serious cardiovascular events including sudden death in patients with structural cardiac abnormalities or other serious heart problems,Increased blood pressure and heart rate,Psychiatric adverse reactions including exacerbation of pre-existing psychosis, mania, or aggression,Seizures in patients with history of seizure disorders,Long-term suppression of growth in children,Potential for peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when used with serotonergic drugs,Hematologic effects such as leukopenia and thrombocytopenia
Serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Blood pressure and heart rate increases,Psychiatric adverse events such as psychosis or mania,Growth suppression in pediatric patients,Seizures,Peripheral vasculopathy including Raynaud's phenomenon,Serotonin syndrome when co-administered with serotonergic drugs
Hypersensitivity to methylphenidate or any component of the formulation,Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy,Glaucoma,Hyperthyroidism or thyrotoxicosis,Tics or family history of Tourette's syndrome,Severe hypertension or other cardiovascular conditions,History of drug abuse or dependence
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Glaucoma,Agitated states,History of drug abuse,Concurrent use of MAOIs or within 14 days of discontinuing MAOI,Hypersensitivity to amphetamine products
Take with or without food. High-fat meals may delay the rate of absorption but not the extent. Avoid excessive caffeine intake as it may increase side effects like nervousness and palpitations. Alcohol should be avoided due to risk of altered release and increased adverse effects.
Avoid acidic foods or vitamin C supplements within 1 hour of dosing as they decrease absorption. Grapefruit may increase drug levels. Caffeine and other stimulants should be limited. Avoid alcohol. High-fat meals may delay onset but not overall absorption.
First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (including irritability, dysphoria, and feeding difficulties).
Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularly cardiovascular defects and oral clefts, but absolute risk is low. Second and third trimesters: Exposure may increase risk of preterm delivery, low birth weight, and neonatal withdrawal symptoms including irritability, dysphoria, and feeding difficulties. Chronic use may lead to fetal growth restriction.
Methylphenidate is excreted into breast milk in low concentrations (M/P ratio approximately 2.5). Short-term use is considered compatible with breastfeeding; however, observe infant for agitation, insomnia, and reduced weight gain. Avoid long-acting formulations due to higher milk concentrations.
Amphetamine is excreted into human breast milk. The milk-to-plasma (M/P) ratio is approximately 2.0–3.0. Relative infant dose is estimated at 5–10% of the maternal weight-adjusted dose. Use while breastfeeding is generally not recommended due to potential adverse effects on the infant, including irritability, poor feeding, and insomnia. Consider alternative treatments or discontinue breastfeeding.
Increased clearance and volume of distribution during pregnancy may require dose adjustments. Plasma levels decrease by approximately 50% in the third trimester; consider increasing dose or switching to immediate-release formulation with more frequent dosing. Postpartum, monitor for toxicity as clearance returns to prepregnancy levels.
Pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced hepatic metabolism, and increased renal clearance) can lower amphetamine plasma concentrations. Dose adjustments may be necessary to maintain therapeutic effect; however, formal guidelines are lacking. Use the lowest effective dose and monitor clinical response. Avoid during pregnancy unless potential benefits outweigh risks.
METADATE ER is an extended-release formulation of methylphenidate. Avoid crushing or chewing capsules to prevent rapid release and potential toxicity. Monitor for blood pressure and heart rate changes, especially in patients with pre-existing cardiovascular conditions. Use with caution in patients with a history of seizures or drug dependence. Discontinue if signs of psychosis or severe depression occur.
ADDERALL 5 (amphetamine/dextroamphetamine) is a CNS stimulant. Note that 5 mg is a low starting dose; titrate based on response and tolerability. Avoid use in patients with structural cardiac abnormalities, glaucoma, hyperthyroidism, or history of drug abuse. Monitor for hypertension, tachycardia, and psychiatric symptoms. Can worsen tics or Tourette syndrome. Use with caution with MAOIs (risk of hypertensive crisis).
Take exactly as prescribed; do not crush or chew capsules.,Swallow whole with or without food, usually in the morning.,Report any chest pain, shortness of breath, or fainting immediately.,Avoid alcohol while taking this medication.,Store at room temperature away from moisture and heat.,Do not suddenly stop taking without consulting your doctor.,May impair ability to drive or operate machinery until effects are known.
Take exactly as prescribed; do not increase dose without consulting doctor.,Swallow tablet whole; do not crush or chew.,Avoid taking late in the day to prevent insomnia.,May cause dizziness; avoid driving if affected.,Report chest pain, shortness of breath, or fainting.,May be habit-forming; do not share with others.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about METADATE ER vs ADDERALL 5, answered by our medical review team.
METADATE ER is a CNS Stimulant that works by Methylphenidate is a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their concentrations in the synaptic cleft. It also acts as a weak agonist at serotonin receptors.. ADDERALL 5 is a CNS Stimulant that works by Adderall 5 is a combination of dextroamphetamine and amphetamine, which are central nervous system stimulants. They increase the levels of dopamine and norepinephrine in the synaptic cleft by inhibiting their reuptake and promoting their release from presynaptic neurons.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between METADATE ER and ADDERALL 5 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of METADATE ER is: Initial: 10-20 mg orally once daily in the morning. May increase by 10-20 mg at weekly intervals. Maximum: 60 mg/day.. The standard adult dose of ADDERALL 5 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments at weekly intervals. Maximum: 40 mg/day in divided doses.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between METADATE ER and ADDERALL 5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. METADATE ER is classified as Category C. First trimester: Limited human data; animal studies show no evidence of teratogenicity at clinically relevant doses. Second and third trimesters: Increased risk of premature delive. ADDERALL 5 is classified as Category C. Pregnancy Category C (pre-2015) / Not assigned under current FDA labeling. First trimester: Studies suggest a possible small increased risk of congenital malformations, particularl. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.